NCT04360343 is a Phase 1 clinical trial of Film-coated tablet in Ulcerative Colitis, sponsored by LG Chem.

Who is sponsoring NCT04360343?

NCT04360343 is sponsored by LG Chem.

What drugs are being tested in NCT04360343?

Interventions in NCT04360343: Film-coated tablet.

What condition does NCT04360343 study?

NCT04360343 studies Ulcerative Colitis.

Is NCT04360343 still recruiting?

NCT04360343 is currently completed. Last updated 22 January 2021.

Last reviewed 2021-01-22 · How we verify

NCT04360343

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy Subjects

Completed Phase 1 Last updated 22 January 2021

What this trial tests

Phase 1 trial testing Film-coated tablet in Ulcerative Colitis in 18 participants. Completed in 1 December 2020.

Timeline

1 July 2020

Primary endpoint
1 October 2020

1 December 2020

Quick facts

Lead sponsor	LG Chem
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	18
Start date	1 July 2020
Primary completion	1 October 2020
Estimated completion	1 December 2020
Sites	1 location across South Korea

Drugs / interventions tested

Film-coated tablet

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →

Sponsor

LG Chem — full company profile →

Who can join

Adults 19 to 45, any sex, with Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the pharmacokinetics, pharmacodynamics and safety/tolerability of LC51-0255 film-coated tablet (SG85) with LC51-0255 uncoated tablet (SG82) in healthy subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. · · 2021 · cited 150× · PMID 33983615 · DOI 10.1007/s40265-021-01528-8
Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage.
Khan SA, Goliwas KF, Deshane JS. · · 2021 · cited 17× · PMID 34690821 · DOI 10.3389/fphys.2021.760638

Verify or expand the search:

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other LG Chem trials

Trials by the same sponsor.

NCT07396844 — The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Voluntee · Phase 1 · not yet recruiting
NCT07399470 — A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagl · Phase 1 · active not recruiting
NCT07333742 — A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metfor · Phase 1 · completed
NCT06921395 — Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulat · Phase 4 · recruiting
NCT06743997 — A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04360343 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LG Chem
Last refreshed: 22 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04360343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing